MediWound MDWD 深 沪
已收盘 10-03 16:00:00 美东时间
17.19
+0.120
+0.70%
华盛通- 最 高17.73
- 今 开17.10
- 成交量 5.95万股
- 最 低 16.95
- 昨 收 17.07
- 总市值 1.87亿
- 52周最高 22.505
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 14.14
- 委 比 33.33%
- 总股本 1087.56万
- 历史最高 135.17
- 量 比 0.72
- 振 幅 4.57%
- 历史最低 7.10
- 每 手 1
- 风险率 1.51%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多MediWound Announces $30 Million Direct Offering to Boost Operations
Mediwound ( ($MDWD) ) has shared an announcement. On September 29, 2025, MediWo...
09-29 21:19
MediWound announces $30 million registered direct offering; shares down over 7%
MediWound (NASDAQ:MDWD) announced on Monday that it has entered into a definitive securities purchase agreement for the sale and purchase of 1.73 million ordinary shares of the company at $17.30 per s...
09-29 20:57
MediWound Secures TGA Approval For NexoBrid In Australia For Adult And Pediatric Patients With Thermal Burns
MediWound Expands Global Reach with Marketing Approval of NexoBrid® in AustraliaTGA Approves NexoBrid® for Adults and Children; Manufacturing Readiness Positions MediWound for 2025 Launch and Asia-Pacific Expansion
09-25 19:56
MediWound Expands Global Reach with Marketing Approval of NexoBrid® in Australia
MediWound's enzymatic therapy NexoBrid® for burn management receives marketing approval in Australia by TGA, expanding its presence to 45 countries. The approval positions MediWound for a 2025 launch in Australia and broader Asia-Pacific expansion. The company's manufacturing readiness supports global demand.
09-25 11:30
MediWound’s NexoBrid® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association Congress
<p>MediWound’s NexoBrid® will be showcased in 36 scientific presentations at the 21st European Burns Association Congress in Berlin, highlighting its role in advancing burn care. Data presented will demonstrate NexoBrid’s benefits for pediatric, elderly, and critically burned patients, including improved survival, recovery, and scar outcomes, as well as infection control and modulation of systemic inflammatory responses. Comparative and long-term...
09-02 11:30
MediWound to Present at the H.C. Wainwright 27th Annual Global Investment Conference
MediWound Ltd. (Nasdaq: MDWD) announced that its CEO, Ofer Gonen, will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025. The event will be available live via webcast. MediWound, a leader in enzymatic therapies for tissue repair, markets NexoBrid® for eschar removal in burns and is developing EscharEx® for chronic wounds.
08-20 11:30
MediWound Executives Purchase Shares, Signaling Confidence
An announcement from Mediwound ( ($MDWD) ) is now available. On August 18, 2025...
08-19 19:27
MediWound Q2 EPS $(1.23) Misses $(0.57) Estimate, Sales $5.708M Beat $5.677M Estimate
MediWound (NASDAQ:MDWD) reported quarterly losses of $(1.23) per share which missed the analyst consensus estimate of $(0.57) by 115.03 percent. This is a 80.88 percent decrease over losses of $(0.68) per share from the
08-14 19:02
Earnings Scheduled For August 14, 2025
Companies Reporting Before The Bell • Sunlands Technology (NYSE:STG) is likely ...
08-14 16:32
MediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers
<p>MediWound Ltd. announced the publication of new Phase II data for EscharEx® in the journal <em>Advances in Wound Care</em>. The study, involving 119 patients with chronic venous leg ulcers (VLUs), demonstrated a strong correlation between wound bed preparation (WBP) and wound closure. Key findings include that wounds achieving WBP were 4.1 times more likely to close compared to those that did not, and early WBP within 14 days significantly inc...
08-13 12:45
